Nicholas Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Nicholas Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-14,615	Closed	-$6M	–	336
2014 Q4	$6M	Buy	14,615 +18	+0.1%	+$7.08K	0.37%	83
2014 Q3	$5.26M	Buy	14,597 +258	+2%	+$86.5K	0.33%	79
2014 Q2	$4.05M	Buy	14,339 +4,138	+41%	+$1.23M	0.24%	140
2014 Q1	$3.06M	Buy	10,201 +1,963	+24%	+$605K	0.25%	130
2013 Q4	$2.27M	Sell	8,238 -954	-10%	-$274K	0.17%	183
2013 Q3	$2.88M	Buy	9,192 +776	+9%	+$204K	0.24%	125
2013 Q2	$1.89M	Buy	+8,416	New	+$1.96M	0.18%	187

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Nicholas Investment Partners's REGN Position: Q1 2015 in Review

Nicholas Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2015, closing a stake of 14,615 shares — an estimated $6M sold.

Nicholas Investment Partners first reported a position in REGN in Q2 2013 and held it in 7 quarters. The position peaked at $6M in Q4 2014. 509 funds tracked by Wall St. Rank hold REGN as of Q1 2015.

Nicholas Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Nicholas Investment Partners sold 14,615 Regeneron Pharmaceuticals shares in Q1 2015, an estimated $6M.
Nicholas Investment Partners first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Nicholas Investment Partners's Regeneron Pharmaceuticals position peaked at $6M in Q4 2014.
509 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2015.

Based on Nicholas Investment Partners's 13F filing for Q1 2015, filed 15 May 2015.